{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:46:47Z","timestamp":1754153207169,"version":"3.41.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,22]]},"DOI":"10.7759\/cureus.88533","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T17:48:16Z","timestamp":1753206496000},"source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetic-Pharmacogenetic (PopPK-PGx) Model of Efavirenz in HIV-1-Infected Patients"],"prefix":"10.7759","author":[{"given":"Katarina","family":"Vucicevic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danica","family":"Michalickova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bozana","family":"Obradovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jovan","family":"Ranin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djordje","family":"Jevtovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Relja","family":"Lukic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordana","family":"Dragovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1086\/499369","article-title":"Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance","volume":"42","author":"Nolan D","year":"2006","unstructured":"Nolan D, Phillips E, Mallal S. Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance. Clin Infect Dis. 2006, 42:408-10. 10.1086\/499369","journal-title":"Clin Infect Dis"},{"key":"ref2","unstructured":"European AIDS Clinical Society (EACS) Guidelines version 12.0. (2023). Accessed. April 17, 2025: https:\/\/www.eacsociety.org\/media\/guidelines-12.0.pdf."},{"key":"ref3","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. (2024). Accessed. April 17, 2025: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv."},{"key":"ref4","unstructured":"Update of recommendations on first- and second-line antiretroviral regimens. (2019). Accessed. April 17, 2025: https:\/\/iris.who.int\/bitstream\/handle\/10665\/325892\/WHO-CDS-HIV-19.15-eng.pdf?sequence=1."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz329","article-title":"Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations","volume":"74","author":"Ayuso P","year":"2019","unstructured":"Ayuso P, Neary M, Chiong J, Owen A. Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations. J Antimicrob Chemother. 2019, 74:3281-90. 10.1093\/jac\/dkz329","journal-title":"J Antimicrob Chemother"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1086\/655470","article-title":"Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study","volume":"202","author":"Ribaudo HJ","year":"2010","unstructured":"Ribaudo HJ, Liu H, Schwab M, et al.. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis. 2010, 202:717-22. 10.1086\/655470","journal-title":"J Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.208","article-title":"Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz","volume":"54","author":"Abdelhady AM","year":"2014","unstructured":"Abdelhady AM, Desta Z, Jiang F, Yeo CW, Shin JG, Overholser BR. Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz. J Clin Pharmacol. 2014, 54:87-96. 10.1002\/jcph.208","journal-title":"J Clin Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-015-0004-2","article-title":"CYP2B6*6, CYP2B6*18, body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV\/AIDS and TB cohort in Zimbabwe","volume":"16","author":"Dhoro M","year":"2015","unstructured":"Dhoro M, Zvada S, Ngara B, Nhachi C, Kadzirange G, Chonzi P, Masimirembwa C. CYP2B6*6, CYP2B6*18, body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV\/AIDS and TB cohort in Zimbabwe. BMC Pharmacol Toxicol. 2015, 16:10.1186\/s40360-015-0004-2","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01537-08","article-title":"Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients","volume":"53","author":"Cabrera SE","year":"2009","unstructured":"Cabrera SE, Santos D, Valverde MP, Dom\u00ednguez-Gil A, Gonz\u00e1lez F, Luna G, Garc\u00eda MJ. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob Agents Chemother. 2009, 53:2791-8. 10.1128\/AAC.01537-08","journal-title":"Antimicrob Agents Chemother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.271","article-title":"Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals","volume":"85","author":"Arab-Alameddine M","year":"2009","unstructured":"Arab-Alameddine M, Di Iulio J, Buclin T, et al.. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther. 2009, 85:485-94. 10.1038\/clpt.2008.271","journal-title":"Clin Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00194-11","article-title":"Population pharmacokinetic\/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients","volume":"55","author":"S\u00e1nchez A","year":"2011","unstructured":"S\u00e1nchez A, Cabrera S, Santos D, Valverde MP, Fuertes A, Dom\u00ednguez-Gil A, Garc\u00eda MJ. Population pharmacokinetic\/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients. Antimicrob Agents Chemother. 2011, 55:5314-24. 10.1128\/AAC.00194-11","journal-title":"Antimicrob Agents Chemother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03516.x","article-title":"A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans","volume":"68","author":"Mukonzo JK","year":"2009","unstructured":"Mukonzo JK, R\u00f6shammar D, Waako P, et al.. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol. 2009, 68:690-9. 10.1111\/j.1365-2125.2009.03516.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-13-112","article-title":"PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV\/AIDS patients","volume":"13","author":"Swart M","year":"2012","unstructured":"Swart M, Whitehorn H, Ren Y, Smith P, Ramesar RS, Dandara C. PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV\/AIDS patients. BMC Med Genet. 2012, 13:10.1186\/1471-2350-13-112","journal-title":"BMC Med Genet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/01213011-200512000-00004","article-title":"Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz","volume":"15","author":"Klein K","year":"2005","unstructured":"Klein K, Lang T, Saussele T, et al.. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics. 2005, 15:816-73. 10.1097\/01213011-200512000-00004","journal-title":"Pharmacogenet Genomics"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.154","article-title":"Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia","volume":"85","author":"Stocco G","year":"2009","unstructured":"Stocco G, Cheok MH, Crews KR, et al.. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther. 2009, 85:164-72. 10.1038\/clpt.2008.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1477","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and efavirenz-containing antiretroviral therapy","volume":"106","author":"Desta Z","year":"2019","unstructured":"Desta Z, Gammal RS, Gong L, et al.. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and efavirenz-containing antiretroviral therapy. Clin Pharmacol Ther. 2019, 106:726-33. 10.1002\/cpt.1477","journal-title":"Clin Pharmacol Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000098","article-title":"CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients","volume":"36","author":"Olagunju A","year":"2014","unstructured":"Olagunju A, Siccardi M, Amara A, Jevtovic D, Kusic J, Owen A, Dragovic G. CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients. Ther Drug Monit. 2014, 36:734-8. 10.1097\/FTD.0000000000000098","journal-title":"Ther Drug Monit"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit466","article-title":"Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia","volume":"209","author":"Bertrand J","year":"2014","unstructured":"Bertrand J, Verstuyft C, Chou M, et al.. Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. J Infect Dis. 2014, 209:399-408. 10.1093\/infdis\/jit466","journal-title":"J Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.61","article-title":"Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro - in vivo extrapolation model","volume":"92","author":"Siccardi M","year":"2012","unstructured":"Siccardi M, Almond L, Schipani A, et al.. Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro - in vivo extrapolation model. Clin Pharmacol Ther. 2012, 92:494-502. 10.1038\/clpt.2012.61","journal-title":"Clin Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2003.22","article-title":"Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection","volume":"73","author":"Csajka C","year":"2003","unstructured":"Csajka C, Marzolini C, Fattinger K, et al.. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther. 2003, 73:20-30. 10.1067\/mcp.2003.22","journal-title":"Clin Pharmacol Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2007.12.002","article-title":"Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R","volume":"90","author":"Comets E","year":"2008","unstructured":"Comets E, Brendel K, Mentr\u00e9 F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed. 2008, 90:154-66. 10.1016\/j.cmpb.2007.12.002","journal-title":"Comput Methods Programs Biomed"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1148-7","article-title":"Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children","volume":"68","author":"Viljoen M","year":"2012","unstructured":"Viljoen M, Karlsson MO, Meyers TM, Gous H, Dandara C, Rheeders M. Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children. Eur J Clin Pharmacol. 2012, 68:339-47. 10.1007\/s00228-011-1148-7","journal-title":"Eur J Clin Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.119.086348err","article-title":"Correction to \"efavirenz metabolism: influence of polymorphic CYP2B6 variants and stereochemistry\"","volume":"47","year":"2019","unstructured":"Correction to \"efavirenz metabolism. influence of polymorphic CYP2B6 variants and stereochemistry\". Drug Metab Dispos. 2019, 47:10.1124\/dmd.119.086348err","journal-title":"Drug Metab Dispos"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12934","article-title":"The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children","volume":"82","author":"Bienczak A","year":"2016","unstructured":"Bienczak A, Cook A, Wiesner L, et al.. The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. Br J Clin Pharmacol. 2016, 82:185-98. 10.1111\/bcp.12934","journal-title":"Br J Clin Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318274197e","article-title":"Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor","volume":"35","author":"Cortes CP","year":"2013","unstructured":"Cortes CP, Siccardi M, Chaikan A, Owen A, Zhang G, la Porte CJ. Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. Ther Drug Monit. 2013, 35:78-83. 10.1097\/FTD.0b013e318274197e","journal-title":"Ther Drug Monit"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.11.012","article-title":"Efavirenz pharmacogenetics in a cohort of Italian patients","volume":"47","author":"Cusato J","year":"2016","unstructured":"Cusato J, Tomasello C, Simiele M, et al.. Efavirenz pharmacogenetics in a cohort of Italian patients. Int J Antimicrob Agents. 2016, 47:117-23. 10.1016\/j.ijantimicag.2015.11.012","journal-title":"Int J Antimicrob Agents"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ317","article-title":"Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study","volume":"61","author":"Olagunju A","year":"2015","unstructured":"Olagunju A, Bolaji O, Amara A, et al.. Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study. Clin Infect Dis. 2015, 61:453-63. 10.1093\/cid\/civ317","journal-title":"Clin Infect Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1236","article-title":"Ensembl 2013","volume":"41","author":"Flicek P","year":"2013","unstructured":"Flicek P, Ahmed I, Amode MR, et al.. Ensembl 2013. Nucleic Acids Res. 2013, 41:48-55. 10.1093\/nar\/gks1236","journal-title":"Nucleic Acids Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/390579-population-pharmacokinetic-pharmacogenetic-poppk-pgx-model-of-efavirenz-in-hiv-1-infected-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T17:48:18Z","timestamp":1753206498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/390579-population-pharmacokinetic-pharmacogenetic-poppk-pgx-model-of-efavirenz-in-hiv-1-infected-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.88533","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,22]]}}}